



PRIX GALIEN KOREA



CHARTER OF THE PRIX GALIEN KOREA COMMITTEE



The Prix Galien honors excellence and innovation in life sciences, recognizing products and individuals that demonstrate outstanding scientific advancement and meaningful contributions to global health. The Korea program celebrates achievements in pharmaceutical, biotechnology, diagnostic, digital health, and medical technology innovation, with a focus on products that have advanced human health through rigorous science and ethical development.

To be eligible, products must have received marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) in Korea by December 31 of the year preceding the award, but not more than five years earlier than December 31 of that year, unless the award is for a new and innovative indication, which must have been added within the previous five years. Please note that the Best Digital Health Solution and Best Startup categories do not require MFDS marketing approval, reflecting the early-stage and digital nature of innovations in these fields.

The committee will award five prizes:

- the Best Pharmaceutical Agent (i.e., small molecule),
 - the Best Biotechnology Product,
 - the Best Medical Technology,
- the Best Digital Health Solution,
 - the Best Startup.

Candidates may come from any therapeutic category and will be evaluated against one another based on scientific merit rather than commercial considerations.

The prizes will be awarded for pharmaceutical science that improves the human condition, principally based on two criteria:

1. What was innovative in the course of this product's scientific development, application or clinical utility?
2. What was learned for the future of biomedical science from this product's introduction to the clinic?

Criteria that will not be considered are the size of the market, the size of the company, the cost of development or the contingencies of distribution.

The awards committee is composed of eight distinguished members appointed by the Board of the Galien Foundation. Members will be selected for their exceptional academic credentials, expertise in human therapeutics, and deep understanding of healthcare issues. Committee members typically serve one term of three years, with the possibility of a second term, and terms will be staggered to ensure continuity. The Board, in consultation with the committee, will appoint a Chair for a two-year term. Nominations for committee membership may come from current or former committee members, academic and research institutions, or scientific divisions within companies developing human therapeutics.

All committee deliberations will be conducted privately and independently. Decisions regarding award recipients are final and made solely by the committee, without influence from the Foundation's Board, member organizations, or sponsors.